LYEL
Price
$8.15
Change
-$0.04 (-0.49%)
Updated
Oct 16, 04:59 PM (EDT)
Capitalization
238.68M
25 days until earnings call
Intraday BUY SELL Signals
XBI
Price
$144.36
Change
-$5.42 (-3.62%)
Updated
Oct 16, 04:59 PM (EDT)
Net Assets
10.37B
Intraday BUY SELL Signals
Interact to see
Advertisement

LYEL vs XBI

LYEL vs XBI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
LYEL vs. XBI commentary
Oct 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LYEL is a Hold and XBI is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for LYEL with price predictions
Oct 15, 2026

LYEL's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for LYEL turned positive on October 15, 2026. Looking at past instances where LYEL's MACD turned positive, the stock continued to rise in 41 of 47 cases over the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LYEL's RSI Oscillator exited the oversold zone, 28 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

Following a +9.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where LYEL advanced for three days, in 201 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

LYEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day moving average for LYEL crossed bearishly below the 50-day moving average on September 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LYEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for LYEL entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. LYEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.021) is normal, around the industry mean (26.782). P/E Ratio (3.025) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. LYEL's P/S Ratio (10000.000) is very high in comparison to the industry average of (437.542).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for XBI with price predictions
Oct 15, 2026

Momentum Indicator for XBI turns negative, indicating new downward trend

XBI saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 83 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

XBI moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for XBI crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for XBI entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +0.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 297 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

TECHNICAL ANALYSIS
Technical Analysis
LYELXBI
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
N/A
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 17 days ago
90%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 16, 2026
Stock price -- (LYEL: $8.19)
Brand notoriety:
Market capitalization --

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LYEL’s FA Score shows that 0 FA rating(s) are green while .

  • LYEL’s FA Score: 0 green, 5 red.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LYEL’s TA Score shows that 4 TA indicator(s) are bullish.

  • LYEL’s TA Score: 4 bullish, 3 bearish.

Price Growth

LYEL (@Biotechnology) experienced а -6.83% price change this weekfor the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.28%. For the same industry, the average monthly price growth was -17.87%, and the average quarterly price growth was -21.14%.

Reported Earning Dates

LYEL is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Biotechnology (-10.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
LYEL
Daily Signal:
Gain/Loss:
XBI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JMBS42.850.22
+0.52%
Janus Henderson Mortgage-Backed Securities ETF (JMBS)
QMAR38.440.02
+0.06%
FT Vest Nasdaq-100 Buffer ETF - March (QMAR)
WDAF30.58N/A
N/A
WisdomTree Asia Defense Fund
MYCF25.01-0.01
-0.06%
State Street My2026 Corporate Bond ETF (MYCF)
EGGY30.23-0.12
-0.40%
NestYield Dynamic Income ETF (EGGY)

LYEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, LYEL has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LYEL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYEL
1D Price
Change %
LYEL100%
+2.50%
VCYT - LYEL
46%
Loosely correlated
+2.02%
ABEO - LYEL
45%
Loosely correlated
+6.65%
SLDB - LYEL
42%
Loosely correlated
+5.03%
EDIT - LYEL
42%
Loosely correlated
+7.49%
VYGR - LYEL
40%
Loosely correlated
+2.49%
More